A Study Comparing Two Different Chemotherapy Types in Chinese Patients With Advanced Non Small Cell Lung Cancer

Lilly

Status and phase

Completed

Phase 3

Conditions

Non Small Cell Lung Cancer

Treatments

Drug: Cisplatin

Drug: Gemcitabine

Drug: Pemetrexed

Study type

Interventional

Funder types

Industry

Identifiers

NCT01005680

12878

H3E-CR-JMIL (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to compare the efficacy and safety of two different chemotherapy types in the first line treatment of advanced Non-Small Cell Lung Cancer (NSCLC).

Enrollment

256 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Present with histologically proven or cytological diagnosis of non-squamous non-small cell lung cancer (NSCLC) Stage IIIB or IV.
Participants must agree to use a reliable method of birth control during the study and for 3 months following the last dose of study drug.
Female participants must not be pregnant.
No prior systemic chemotherapy for lung cancer.
At least one unidimensionally measurable lesion meeting Response Evaluation Criteria in Solid Tumors.
Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1.
Adequate organ function.
Prior radiation therapy allowed to <25% of the bone marrow.
Signed informed consent document on file.
Estimated life expectancy of greater than or equal to 12 weeks.
Participant compliance and geographic proximity that allow adequate follow up.

Exclusion criteria

Peripheral neuropathy of great than or equal to Common Terminology Criteria for Adverse Events (CTCAE) Grade 1.
Inability to comply with protocol or study procedures.
A serious concomitant systemic disorder that, in the opinion of the investigator, would compromise the participant's ability to complete the study.
A serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease, as defined by the New York Heart Association Class III or IV.
Second primary malignancy that is clinically detectable at the time of consideration for study enrollment.
Documented brain metastases unless the participant has completed successful local therapy for central nervous system metastases and has not taken corticosteroids for at least 4 weeks before enrollment.
Presence of clinically significant third-space fluid collections, for example, ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to study entry.
Significant weight loss (that is, greater than or equal to 10%) over the previous 6 weeks before study entry.
Concurrent administration of any other anti-tumor therapy.
Inability to interrupt aspirin or other non-steroidal anti-inflammatory agents for a 5-day period (8-day period for long-acting agents, such as piroxicam).
Inability or unwillingness to take folic acid or vitamin B12 supplementation.
Inability to take corticosteroids.
Pregnant or breast-feeding.
Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an off-label use of an investigational drug or device (other than the study drug), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.